title: [The influence of the Travalert(®) dosing aid on medical treatment compliance and the quality of life of glaucoma patients].
abstract: OBJECTIVE
  To study compliance in the medical treatment of glaucoma, its possible association with other factors, and quality of life of patients with glaucoma.
  
  
  METHODS
  Longitudinal prospective study of 60 patients with ocular hypertension or glaucoma who were treated with travoprost, or with a fixed combination of travoprost/timolol nightly. All subjects were given a Travalert(®) dosing aid and were reviewed after one and four months. Strict and relative compliance data were collected on each visit. The relationship between compliance and other variables was studied using univariate analysis. To analyse quality of life, patients were given self-assessment STAI anxiety questionnaires after the first and last visits.
  
  
  RESULTS
  Relative compliance for the four months was significantly greater than the strict compliance (P=.001). In the group of least compliance the number of patients on treatment with combination therapy was significantly higher than those on monotherapy. In the lost cases, the number of men was significantly higher than women. No association was found in the other variables. The anxiety was similar to that in the normal population.
  
  
  CONCLUSIONS
  Compliance is very important in the treatment of glaucoma, and our study provides objective data through the use of Travalert dosing aid with relative compliances of 70%. Patients with combined therapies have lower compliance than those on monotherapy.
authors: Departamento de Glaucoma, Hospital Clínico San Carlos, Madrid, España. m.sanchezpulgarin@gmail.com
authors: M
authors: M
authors: Sánchez-Pulgarín
authors: J M
authors: JM
authors: Martínez-de-la-Casa
authors: A
authors: A
authors: Escalada
authors: F
authors: F
authors: Sáenz-Francés
authors: J
authors: J
authors: García-Feijoó
authors: J
authors: J
authors: García Sánchez
mesh_terms: D060433:Administration, Ophthalmic; D000368:Aged; D001007:Anxiety / Q000209:etiology / Q000523:psychology; D003008:Cloprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005901:Glaucoma / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D007322:Instillation, Drug; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000523:psychology; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D011446:Prospective Studies; D011788:Quality of Life; D017010:Reminder Systems / Q000295:instrumentation*; D011795:Surveys and Questionnaires; D013999:Timolol / Q000008:administration & dosage / Q000627:therapeutic use*; D000069557:Travoprost
chemical_list: D004338:Drug Combinations; D009883:Ophthalmic Solutions; D003008:Cloprostenol; D013999:Timolol; D000069557:Travoprost